A Novel Biomaterial for Osteotropic Drug Nanocarriers: Synthesis and Biocompatibility Evaluation of a PLGA–ALE Conjugate

Pignatello, Rosario; Cenni, E.; Micieli, Dorotea; Fotia, Caterina; Salerno, Manuela; Granchi, Donatella; Avnet, Sofia; Sarpietro, Maria Grazia; Castelli, Francesco; Baldini, Nicola

doi:10.2217/17435889.4.2.161

Cited by 69 publications

(56 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Disadvantages of BPs and their advances as novel drug delivery systems. DOI: 10.3109/10717544.2013.870259 PLGA-ALD NPs are suitable for the intravenous administration, and the drug-loading could make them a promising tool for delivering the BPs for treating OP (Cenni et al, 2008;Pignatello et al, 2009). Thus the developed nanoparticulate drug delivery did not show any bleeding from esophagus and no hemolysis was recorded.…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

Context: Bisphosphonates (BPs) are widely used for prevention and treatment of osteoporosis. BPs are known as gold standard for osteoporosis (OP) treatment due to their positive results in clinical studies. But some serious side effects are associated with BPs like gastrointestinal adverse effect i.e. esophagitis and ulcer of esophagus. Oral bioavailability (BA) of BPs ranges from 0.6 to 1% due to poor absorption through gastrointestinal tract (GIT). Objective: The main objective of this review is to explore the role of novel drug delivery systems (DDSs) for the delivering of BPs and minimizing the drawbacks associated with them. Methods: The current review is focusing on classification, mechanism of action, and limitations of BPs, and is also dwelling on the use of novel DDSs like nanoparticles, liposomes, topical, transdermal systems, implants, bisphosphonate osteotropic DDS (BP-ODDS), microspheres, and calcium phosphate cements (CPCs) for BPs. This review also gives a critically reviewed compilation of the various in vitro and in vivo studies conducted till date. Conclusion: On the basis of the exhaustive literature, it has been found that the novel DDS minimizes the side effects associated with BPs and enhances the BA. The advance drug delivery has a greater impact on reducing the undesirable effects and increasing the BA of BPs.

show abstract

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In conclusion, PLGA-ALE conjugate did not cause either haemolysis on human erythrocytes, or alterations of the plasmatic phase of coagulation or cytotoxic effects on endothelial cells and trabecular osteoblasts [31]. …”

Section: The Scientific and Technical Rationale For A New Targeting Smentioning

confidence: 76%

“…Finally, PLGA-ALE NP were then loaded with a model cytotoxic drug, doxorubicin (DOX) and tested in vitro and in vivo. [31]. In the first case, a solution of Resomer ® RG 502 H in DMSO and dichloromethane (DCM) (1:1) was activated at 0°C for 2 h by N'-(3-dimethylaminopropyl)-N-ethyl carbodiimide hydrochloride (EDAC), in the presence of 1-hydroxy-benzotriazole (HOBt) and triethylamine.…”

Section: The Scientific and Technical Rationale For A New Targeting Smentioning

confidence: 99%

“…Both methods resulted in similar production yields (70-75%) and purity of the final conjugate, therefore the first method could be better proposed as more direct and simple. The chemical structure of the PLGA-ALE conjugate was confirmed by MALDI-TOF MS and 1 H-NMR; analytical details are available [31]. In the view of using the PLGA-ALE copolymer to prepare bone-targeted NPs, the conjugate was evaluated for blood and cyto-compatibility, to individuate any negative effect which might have precluded any further biological investigation.…”

Section: The Scientific and Technical Rationale For A New Targeting Smentioning

confidence: 99%

See 1 more Smart Citation

PLGA-Alendronate Conjugate as a New Biomaterial to Produce Osteotropic Drug Nanocarriers

Pignatello¹

2011

Biomaterials Applications for Nanomedicine

Self Cite

View full text Add to dashboard Cite

“…For example, an alendronate-PLGA conjugate was used to prepare 200-300 nm nanoparticles that could be directed to the bones. 92 Alendronate-PLGA conjugate nanoparticles do not have cytotoxic effects on endothelial cells or trabecular osteoblasts. These nanoparticles adsorb onto hydroxyapatite to a greater extent than bare PLGA nanoparticles.…”

Section: Bisphosphonate-functional Plga Nanoparticlesmentioning

confidence: 97%

Concepts and practices used to develop functional PLGA-based nanoparticulate systems

Sah¹,

Thoma²,

Desu³

et al. 2013

IJN

194

127

View full text Add to dashboard Cite

Abstract:The functionality of bare polylactide-co-glycolide (PLGA) nanoparticles is limited to drug depot or drug solubilization in their hard cores. They have inherent weaknesses as a drug-delivery system. For instance, when administered intravenously, the nanoparticles undergo rapid clearance from systemic circulation before reaching the site of action. Furthermore, plain PLGA nanoparticles cannot distinguish between different cell types. Recent research shows that surface functionalization of nanoparticles and development of new nanoparticulate dosage forms help overcome these delivery challenges and improve in vivo performance. Immense research efforts have propelled the development of diverse functional PLGA-based nanoparticulate delivery systems. Representative examples include PEGylated micelles/nanoparticles (PEG, polyethylene glycol), polyplexes, polymersomes, core-shelltype lipid-PLGA hybrids, cell-PLGA hybrids, receptor-specific ligand-PLGA conjugates, and theranostics. Each PLGA-based nanoparticulate dosage form has specific features that distinguish it from other nanoparticulate systems. This review focuses on fundamental concepts and practices that are used in the development of various functional nanoparticulate dosage forms. We describe how the attributes of these functional nanoparticulate forms might contribute to achievement of desired therapeutic effects that are not attainable using conventional therapies. Functional PLGA-based nanoparticulate systems are expected to deliver chemotherapeutic, diagnostic, and imaging agents in a highly selective and effective manner.

show abstract

A Novel Biomaterial for Osteotropic Drug Nanocarriers: Synthesis and Biocompatibility Evaluation of a PLGA–ALE Conjugate

Abstract: The prepared conjugate represents a novel biomaterial that is able to provide nanoparticles, which can be further loaded with drugs, such as anticancer agents, and addressed to osteolytic or other bone diseases.

Cited by 69 publications

References 36 publications

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Bisphosphonates: therapeutics potential and recent advances in drug delivery

PLGA-Alendronate Conjugate as a New Biomaterial to Produce Osteotropic Drug Nanocarriers

Concepts and practices used to develop functional PLGA-based nanoparticulate systems

Contact Info

Product

Resources

About